JMV3315

Primary Application: High-Potency Dopamine Stimulation and Neurological Research

Fundamental Information

• Amino Acid Sequence: Thr-Lys-Tyr-Ala-Ala (TKYAA)

• Classification: Pentapeptide Acein Analog

• Key Modification: Substitution of Phenylalanine with Tyrosine

• Binding Potency: 3.7 nM (Approximately 3.5x higher than native fragment)

Detailed Overview

JMV3315 is a streamlined, high-potency version of the Acein peptide. Through structural engineering, researchers identified the most active part of the Acein sequence—the final five amino acids—and modified it to create this optimized version. By swapping the specific amino acid Phenylalanine for Tyrosine at the third position, scientists created a peptide that binds to its target in the brain with significantly higher strength than the original nonapeptide.

Pharmacological tests confirmed that JMV3315 is approximately 3.5 times more effective than the original Acein fragment at triggering dopamine release in motor-control areas. Because JMV3315 is a much smaller molecule than its predecessor, it offers improved metabolic stability and potentially better passage through the blood-brain barrier. This makes it a leading research candidate for developing targeted treatments for central nervous system disorders characterized by dopamine deficiency and age-related cognitive decline.

Scientific References

1. Lucas-Valmalle C, et al. “The C-terminal pentapeptide acein analogue (JMV3315) stimulates dopamine release in the brain.” Australian Journal of Chemistry. 2023;76(8):448-454.